Noscendo's DISQVER® platform represents a significant advancement in digital pathogen diagnostics, utilizing next-generation sequencing (NGS) to identify a vast array of microbes from a single blood sample. This innovative technology can detect over 16,000 microbes, including 1,500 known pathogens such as bacteria, DNA viruses, fungi, and parasites, within approximately 24 hours. By analyzing cell-free DNA (cfDNA) from patient samples, DISQVER® employs sophisticated bioinformatics algorithms to compare the sequenced data against Noscendo's clinical-grade genome reference database. This rapid and comprehensive diagnostic capability allows for timely and precise identification of pathogens, which is crucial for managing conditions like bloodstream infections and sepsis.

The advantages of DISQVER® extend beyond speed; it offers a higher sensitivity and specificity compared to traditional blood culture methods, enabling the detection of difficult-to-cultivate pathogens and providing reliable results even during ongoing anti-infective therapy. This technology not only enhances the diagnostic process but also supports healthcare providers in making informed treatment decisions, ultimately aiming to improve patient outcomes. Noscendo's commitment to revolutionizing infection diagnostics is underscored by its collaborations with leading medical institutions and health insurance providers, further solidifying its position as a leader in the field of NGS-based diagnostics for critically ill patients.

Germany

Noscendo GmbH, a Duisburg (Germany) based molecular diagnostics company, changes the way infection causative microbes are identified. Introducing a paradigm shift using proprietary algorithms and software harnessing next generation sequencing of cell free nucleic acids isolated from patient samples Noscendo brings the concept of liquid biopsy into the field of infectious diseases.
Noscendo’ s software solution is capable of differentiating infection from non-infectious signals and thereby aiding intensive care clinicians in their daily task to find the right decisions, enabling a targeted and successful treatment in an actionable timeframe.

Noscendo

Company Details